| Identification | Back Directory | [Name]
M348 | [CAS]
899713-86-1 | [Synonyms]
M348
ML348
CS-2370
GNF-Pf-1127
ML-348 (ML348)
ML 348;GNF-PF-1127
alpha-synuclein 1-95, human
N-[2-Chloro-5-(trifluoromethyl)phenyl]-4-(2-furanylcarbonyl)-1-piperazineacetamide
1-Piperazineacetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-4-(2-furanylcarbonyl)- | [EINECS(EC#)]
809-791-4 | [Molecular Formula]
C18H17ClF3N3O3 | [MDL Number]
MFCD05123530 | [MOL File]
899713-86-1.mol | [Molecular Weight]
415.79 |
| Chemical Properties | Back Directory | [Boiling point ]
546.2±50.0 °C(Predicted) | [density ]
1.422±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 25 mg/mL (60.13 mM; Need ultrasonic) | [form ]
Powder | [pka]
13.13±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ML348 is a reversible LYPLA1 inhibitor. It is 14-fold selective for LYPLA1 over LYPLA2 and demonstrates little activity against a panel of more than 20 other serine hydrolases. | [Biochem/physiol Actions]
ML348 is a substrate-competitive, reversible and APT1-selective acyl-protein thioesterase (APT) inhibitor (IC50/Ki = 840 nM/300 nM against APT1; IC50 & Ki >10 μM against APT2). ML348 effectively inhibits cellular APT1 activity in cultures (by >95% in HEK293T & mouse T cells; 5 μM for 4 h) and in mice in vivo (by >90% in lung/heart/kidney and by ~50% in brain tissue 4 h post 50 mg/kg i.p. dosing) without affecting more than 15 cellular serine hydrolases and APT2. | [in vivo]
ML348 (50 mg/kg, i.p., 3 hours) shows potent and selective activity in vivo, inhibits LYPLA1 enzymes in heart, kidney and lung in mice[1].
| Animal Model: | C57BL6 male mice (3-4 months)[1] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneal injection; 3 hours | | Result: | Potent and selective inhibited LYPLA1 enzymes in heart, kidney and lung in vivo. |
| [storage]
Store at +4°C |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|